Associated Papers
Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Lin CW et al.
Oncology Letters, 2025
39807107 (PubMed )
Supplement: Supplementary_Data2.pdf
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
39063150 (PubMed )
Supplement: ijms-25-07908-s001.zip › ijms-3103240-supplementary.pdf
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Akkhasutthikun P et al.
Cancer Research and Treatment, 2024
37986562 (PubMed )
Supplement: crt-2023-1108-Supplementary-Table-S10.pdf
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A et al.
Cancer Medicine, 2024
38457233 (PubMed )
Supplement: CAM4-13-e7077-s003.xlsx › Table_S5
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM5_ESM.xlsx › combie_list
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer.
Park IH et al.
Cancer Research and Treatment, 2024
37340844 (PubMed )
Supplement: crt-2023-408_S1_Table.pdf
Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T et al.
Scientific Reports, 2023
37612335 (PubMed )
Supplement: 41598_2023_40271_MOESM1_ESM.pdf
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
37047382 (PubMed )
Supplement: ijms-24-06410-s001.zip › ijms-2177723-supplementary.pdf
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
36128861 (PubMed )
Supplement: jptm-2022-06-11-suppl1.pdf
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
Ntzifa A et al.
Cancers, 2021
34073111 (PubMed )
Supplement: cancers-13-02736-s001.zip › cancers-1192044-supplementary.pdf
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.
Garcia J et al.
Molecular Diagnosis & Therapy, 2021
33660188 (PubMed )
Supplement: 40291_2021_515_MOESM1_ESM.pdf
Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
Song X et al.
British Journal of Cancer, 2020
32782293 (PubMed )
Supplement: 41416_2020_1024_MOESM1_ESM.pdf
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S et al.
Expert Review of Molecular Diagnostics, 2020
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
29141884 (PubMed )
Supplement: aan6566_supplementary_tables.zip › aan6566_Table_S2.xlsx › Table_S2
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma.
Xu T et al.
Theranostics, 2017
28529628 (PubMed )
Supplement: thnov07p1437s1.pdf
Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.
Xu S et al.
Cancer Letters, 2016
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M et al.
Pathology, 2014
Identification of candidate genes for lung cancer somatic mutation test kits.
Chen Y et al.
Genetics and Molecular Biology, 2013
Mutation detection by clonal sequencing of PCR amplicons and grouped read typing is applicable to clinical diagnostics.
Chambers PA et al.
Human Mutation, 2013
22915446 (PubMed )
Supplement: supplement_1.pdf
Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel.
Patel R et al.
Plos One, 2012
Select a paper to view details